A detailed history of Virtus ETF Advisers LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 28,639 shares of SAGE stock, worth $155,796. This represents 0.1% of its overall portfolio holdings.

Number of Shares
28,639
Previous 28,639 -0.0%
Holding current value
$155,796
Previous $311,000 33.76%
% of portfolio
0.1%
Previous 0.16%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.58 - $17.9 $112,930 - $191,064
10,674 Added 59.42%
28,639 $311,000
Q1 2024

May 15, 2024

BUY
$18.62 - $26.95 $48,132 - $69,665
2,585 Added 16.81%
17,965 $336,000
Q4 2023

Feb 15, 2024

BUY
$17.1 - $22.26 $173,394 - $225,716
10,140 Added 193.51%
15,380 $333,000
Q3 2023

Nov 07, 2023

SELL
$16.75 - $48.98 $11,390 - $33,306
-680 Reduced 11.49%
5,240 $107,000
Q2 2023

Aug 14, 2023

SELL
$40.65 - $59.54 $62,316 - $91,274
-1,533 Reduced 20.57%
5,920 $278,000
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $4,956 - $6,193
133 Added 1.82%
7,453 $312,000
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $2,189 - $2,965
-68 Reduced 0.92%
7,320 $279,000
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $3,453 - $4,629
107 Added 1.47%
7,388 $289,000
Q2 2022

Aug 12, 2022

SELL
$27.52 - $37.99 $63,653 - $87,870
-2,313 Reduced 24.11%
7,281 $235,000
Q4 2021

Feb 14, 2022

BUY
$37.06 - $47.11 $122,816 - $156,122
3,314 Added 52.77%
9,594 $408,000
Q3 2021

Nov 15, 2021

SELL
$40.26 - $57.37 $23,068 - $32,873
-573 Reduced 8.36%
6,280 $278,000
Q2 2021

Aug 10, 2021

SELL
$54.88 - $79.29 $109,705 - $158,500
-1,999 Reduced 22.58%
6,853 $389,000
Q1 2021

May 17, 2021

BUY
$70.65 - $96.76 $17,026 - $23,319
241 Added 2.8%
8,852 $663,000
Q4 2020

Feb 12, 2021

SELL
$58.41 - $89.06 $439,885 - $670,710
-7,531 Reduced 46.65%
8,611 $745,000
Q3 2020

Nov 13, 2020

BUY
$41.13 - $62.45 $55,936 - $84,932
1,360 Added 9.2%
16,142 $987,000
Q2 2020

Aug 05, 2020

BUY
$25.95 - $43.15 $174,124 - $289,536
6,710 Added 83.13%
14,782 $615,000
Q1 2020

May 14, 2020

SELL
$26.15 - $77.24 $17,808 - $52,600
-681 Reduced 7.78%
8,072 $232,000
Q4 2019

Feb 13, 2020

BUY
$60.18 - $154.77 $286,998 - $738,098
4,769 Added 119.7%
8,753 $632,000
Q3 2019

Nov 12, 2019

SELL
$140.29 - $189.96 $92,731 - $125,563
-661 Reduced 14.23%
3,984 $559,000
Q2 2019

Aug 13, 2019

BUY
$157.85 - $183.09 $315,700 - $366,180
2,000 Added 75.61%
4,645 $850,000
Q1 2019

May 14, 2019

SELL
$89.33 - $163.65 $27,066 - $49,585
-303 Reduced 10.28%
2,645 $421,000
Q4 2018

Feb 05, 2019

BUY
$81.94 - $139.71 $6,309 - $10,757
77 Added 2.68%
2,948 $282,000
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $283,401 - $346,870
-2,052 Reduced 41.68%
2,871 $406,000
Q2 2018

Aug 10, 2018

BUY
$140.36 - $175.76 $21,334 - $26,715
152 Added 3.19%
4,923 $771,000
Q1 2018

May 14, 2018

BUY
$152.15 - $192.33 $393,155 - $496,980
2,584 Added 118.15%
4,771 $768,000
Q4 2017

Feb 14, 2018

SELL
$60.72 - $167.34 $124,293 - $342,544
-2,047 Reduced 48.35%
2,187 $360,000
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $23,823 - $34,345
388 Added 10.09%
4,234 $264,000
Q2 2017

Aug 14, 2017

BUY
N/A
3,846
3,846 $306,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.